Roivant Sciences (ROIV) vs Zoetis (ZTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Roivant Sciences (ROIV) has outperformed Zoetis (ZTS) over the past year, gaining 119.9% versus a loss of 47.8%. Over five years, ROIV leads with a +488.7% price change compared with -63.0% for ZTS. Zoetis is the larger company by market cap ($30.91 billion vs $25.60 billion), about 1.2 times the size.
Zoetis pays a dividend yielding 2.75%, while Roivant Sciences does not currently pay one. Zoetis converts more of its revenue into profit, with a net margin of 28.2% versus -3629.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ROIV | ZTS |
|---|---|---|
| Share price | $35.44 | $74.81 |
| Market cap | $25.60B | $30.91B |
| 1-day change | +3.60% | +2.37% |
| YTD return | +63.32% | -40.54% |
| 1-year return | +119.85% | -47.83% |
| 5-year return | +488.70% | -63.01% |
| P/E ratio (TTM) | — | 12.03 |
| Forward P/E | — | 11.43 |
| EPS (TTM) | $-0.55 | $6.22 |
| Dividend yield | 0.00% | 2.75% |
| Annual dividend | $0.00 | $2.06 |
| Revenue (latest FY) | $8.26M | $9.47B |
| Revenue growth (YoY) | -71.57% | +2.28% |
| Net income (latest FY) | $-299.77M | $2.67B |
| Gross margin | — | 71.84% |
| Operating margin | -6235.69% | — |
| Net margin | -3629.19% | 28.23% |
| 52-week high | $42.50 | $148.30 |
| 52-week low | $15.99 | $68.77 |
| Distance from 52-week high | -16.61% | -49.55% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +35.67% | +28.33% |
| Average volume | 7.05M | 5.46M |
| Shares outstanding | 722.32M | 413.22M |
| Employees | 721 | 14,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ROIV has outperformed ZTS by 167.7 percentage points over the past year.
- Zoetis offers a meaningfully higher dividend yield (2.75% vs 0.00%).
- Zoetis is more profitable, keeping 28.2 cents of every revenue dollar as net income versus -3629.2 cents for Roivant Sciences.
- Zoetis grew revenue faster in its latest fiscal year (+2.28% vs -71.57%).
About Roivant Sciences
ROIV stock →Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 721 employees
About Zoetis
ZTS stock →Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 14,500 employees
ROIV vs ZTS FAQ
Which is bigger, Roivant Sciences or Zoetis?
Zoetis (ZTS) is larger, with a market capitalization of $30.91B compared with $25.60B for Roivant Sciences (ROIV).
Which stock has performed better over the past year, ROIV or ZTS?
ROIV returned +119.85% over the past 12 months, compared with -47.83% for ZTS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Roivant Sciences or Zoetis?
Zoetis pays a dividend yielding 2.75%, while Roivant Sciences does not currently pay a regular dividend.
Are Roivant Sciences and Zoetis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.